Monopar Therapeutics (NASDAQ:MNPR) Downgraded by Zacks Research to “Hold”

Posted by Brian Himes on Aug 15th, 2026

Zacks Research cut shares of Monopar Therapeutics (NASDAQ:MNPR – Free Report) from a strong-buy rating to a hold rating in a report issued on Thursday morning,Zacks.com reports.

Other analysts have also issued reports about the stock. Barclays reiterated an “overweight” rating and set a $128.00 price target (up from $125.00) on shares of Monopar Therapeutics in a research note on Thursday. Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. HC Wainwright upped their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Finally, BTIG Research increased their target price on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Monopar Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $117.42.

Get Our Latest Report on Monopar Therapeutics

Monopar Therapeutics Trading Up 2.4%

MNPR stock opened at $113.04 on Thursday. The company has a market capitalization of $757.25 million, a PE ratio of -52.09 and a beta of 1.47. Monopar Therapeutics has a 12-month low of $29.18 and a 12-month high of $124.82. The business’s fifty day moving average price is $96.11 and its 200 day moving average price is $71.53.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.02. Research analysts predict that Monopar Therapeutics will post -2.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Monopar Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new position in shares of Monopar Therapeutics during the third quarter worth about $28,000. BNP Paribas Financial Markets increased its stake in shares of Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after buying an additional 349 shares during the period. Meeder Asset Management Inc. acquired a new stake in Monopar Therapeutics in the fourth quarter valued at approximately $65,000. JPMorgan Chase & Co. raised its holdings in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after acquiring an additional 1,821 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Monopar Therapeutics in the second quarter worth approximately $80,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

(Get Free Report)

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.